Do serum C-reactive protein measurements help to discriminate episodes of renal dysfunction in patients after renal transplantation?

Thalidomide reduces serum C-reactive pro

Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy

✍ Igal Kedar; Wilmosh Mermershtain; Hefziba Ivgi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 341 KB

## Abstract Interleukin‐2 (IL‐2) has some antitumor activity in patients with renal cell carcinoma. It has been noted that response to IL‐2 and prognosis may be adversely affected by elevated serum levels of C‐reactive protein (CRP) or interleukin‐6 (IL‐6). We used thalidomide to treat patients wit